Table 1.
Bevacizumab in first-line treatment
| Study | Patients | Study arm (S) | Control arm (C) | Results | |
|---|---|---|---|---|---|
| All patients | High risk | ||||
| Perren et al6 ICON 7 | Stage I–IIA G3 or clear cell or stage IIB–IV | Carboplatin + paclitaxel q3w + bevacizumab 7.5 mg/kg q3w for 12 months | Carboplatin + paclitaxel q3w iv | PFS 19.8 (S) vs 17.4 months (C) OS 45.5 (S) vs 44.6 months (C) |
PFS 15.9 (S) vs 10.5 months (C) OS 39.3 (S) vs 34.5 months (C) |
| Burger et al7 GOG-0218 | Stage III–IV | S1: Carboplatin + paclitaxel q3w + bevacizumab 15 mg/kg q3w from cycle 2 through 6 S2: Carboplatin + paclitaxel q3w + bevacizumab 15 mg/kg q3w from cycle 2 through 22 for 15 months |
Carboplatin + paclitaxel q3w iv + placebo | PFS 11.2 (S1) vs 14.1 (S2) vs 10.3 months (C) OS 38.7 (S1) vs 39.7 (S2) vs 39.3 months (C) |
Stage IV OS 32.6 (C), 34.5 (S1), and 42.8 months (S2) |
| Gonzalez-Martin et al20 OCTAVIA | Stage I–IIA grade 3 or clear cell or stage IIB–IV | Carboplatin q3w + paclitaxel w + bevacizumab 7.5 mg/kg q3w for 12 months | NA | PFS 23.7 months (S) | 18.1 months (S) |
| Oza et al23 ROSiA | Stage IIB–IV or grade 3 stage I–IIA | Carboplatin + paclitaxel q3w + bevacizumab 7.5 or 15 mg/kg q3w for 24 months | NA | PFS 25.5 months (S) | 18.3 months (S) |
Abbreviations: C, control arm; G, grading; NA, not available; PFS, progression-free survival; S, study arm; S1, study arm 1; S2, study arm 2; iv, intravenously; q3w, every 3 weeks; w, weekly.